141 related articles for article (PubMed ID: 29498983)
21. Bevacizumab with dose-dense paclitaxel/carboplatin as first-line chemotherapy for advanced ovarian cancer.
Zhang L; Zhou Q
Eur J Pharmacol; 2018 Oct; 837():64-71. PubMed ID: 30059681
[TBL] [Abstract][Full Text] [Related]
22. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Pujade-Lauraine E; Hilpert F; Weber B; Reuss A; Poveda A; Kristensen G; Sorio R; Vergote I; Witteveen P; Bamias A; Pereira D; Wimberger P; Oaknin A; Mirza MR; Follana P; Bollag D; Ray-Coquard I
J Clin Oncol; 2014 May; 32(13):1302-8. PubMed ID: 24637997
[TBL] [Abstract][Full Text] [Related]
23. Prospective non-interventional BELOVA/BGOG-ov16 study on safety of frontline bevacizumab in elderly patients with FIGO stage IV ovarian cancer: a study of the Belgian and Luxembourg Gynaecological Oncology Group.
Vergote I; Van Nieuwenhuysen E; De Waele S; Vulsteke C; Lamot C; Van den Bulck H; Claes N; Graas MP; Debrock G; Spoormans I; Vuylsteke P; Honhon B; Verhoeven D; De Maeseneer D; Dirix L; Mebis J; Vroman P; Denys H; Martinez Mena C; Pelgrims G; Van Steenberghe M; van Gorp T; Gennigens C
Int J Gynecol Cancer; 2022 Jun; 32(6):753-760. PubMed ID: 35063943
[TBL] [Abstract][Full Text] [Related]
24. Uracil-Tegafur and Oral Leucovorin Combined With Bevacizumab in Elderly Patients (Aged ≥ 75 Years) With Metastatic Colorectal Cancer: A Multicenter, Phase II Trial (Joint Study of Bevacizumab, Oral Leucovorin, and Uracil-Tegafur in Elderly Patients [J-BLUE] Study).
Nishina T; Moriwaki T; Shimada M; Higashijima J; Sakai Y; Masuishi T; Ozeki M; Amagai K; Negoro Y; Indo S; Denda T; Sato M; Yamamoto Y; Nakajima G; Mizuta M; Takahashi I; Hiroshima Y; Ishida H; Maeba T; Hyodo I
Clin Colorectal Cancer; 2016 Sep; 15(3):236-42. PubMed ID: 26778644
[TBL] [Abstract][Full Text] [Related]
25. Bevacizumab improves overall survival in platinum refractory ovarian cancer patients: A retrospective study.
Chikazawa K; Netsu S; Kuwata T; Konno R
Taiwan J Obstet Gynecol; 2018 Dec; 57(6):819-824. PubMed ID: 30545534
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of neoadjuvant chemotherapy containing bevacizumab and interval debulking surgery for advanced epithelial ovarian cancer: A feasibility study.
Komiyama S; Kugimiya T; Kubushiro K
J Surg Oncol; 2018 Sep; 118(4):687-693. PubMed ID: 30206937
[TBL] [Abstract][Full Text] [Related]
27. A phase II study of carboplatin plus weekly paclitaxel with bevacizumab for elderly patients with non-squamous non-small-cell lung cancer (NEJ016).
Miura S; Maemondo M; Iwashima A; Harada T; Sugawara S; Kobayashi K; Inoue A; Nakagawa T; Takiguchi Y; Watanabe H; Ishida T; Terada M; Kagamu H; Gemma A; Yoshizawa H
Invest New Drugs; 2017 Apr; 35(2):227-234. PubMed ID: 28150074
[TBL] [Abstract][Full Text] [Related]
28. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
Zielinski C; Láng I; Inbar M; Kahán Z; Greil R; Beslija S; Stemmer SM; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Petruzelka L; Eniu A; Nisenbaum B; Dank M; Anghel R; Messinger D; Brodowicz T;
Lancet Oncol; 2016 Sep; 17(9):1230-9. PubMed ID: 27501767
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant Chemotherapy Followed by Maintenance Therapy With or Without Bevacizumab in Unresectable High-Grade Serous Ovarian Cancer: A Case-Control Study.
Petrillo M; Paris I; Vizzielli G; Amadio G; Cosentino F; Salutari V; Scambia G; Fagotti A
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S952-8. PubMed ID: 26036187
[TBL] [Abstract][Full Text] [Related]
30. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
Pignata S; Scambia G; Katsaros D; Gallo C; Pujade-Lauraine E; De Placido S; Bologna A; Weber B; Raspagliesi F; Panici PB; Cormio G; Sorio R; Cavazzini MG; Ferrandina G; Breda E; Murgia V; Sacco C; Cinieri S; Salutari V; Ricci C; Pisano C; Greggi S; Lauria R; Lorusso D; Marchetti C; Selvaggi L; Signoriello S; Piccirillo MC; Di Maio M; Perrone F; ; ; ; ;
Lancet Oncol; 2014 Apr; 15(4):396-405. PubMed ID: 24582486
[TBL] [Abstract][Full Text] [Related]
31. An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023.
Shoji T; Komiyama S; Kigawa J; Tanabe H; Kato K; Itamochi H; Fujiwara H; Kamiura S; Hamano T; Sugiyama T;
BMC Cancer; 2018 Jul; 18(1):771. PubMed ID: 30064406
[TBL] [Abstract][Full Text] [Related]
32. Arthralgia in patients with ovarian cancer treated with bevacizumab and chemotherapy.
Ventriglia J; Paciolla I; Pisano C; Tambaro R; Cecere SC; Di Napoli M; Attademo L; Arenare L; Spina A; Russo D; Califano D; Losito NS; Setola SV; Franzese E; De Vita F; Orditura M; Pignata S
Int J Gynecol Cancer; 2021 Jan; 31(1):110-113. PubMed ID: 32796087
[TBL] [Abstract][Full Text] [Related]
33. An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.
Spigel DR; Luft A; Depenbrock H; Ramlau R; Khalil M; Kim JH; Mayo C; Chao GY; Obasaju C; Natale R
Clin Lung Cancer; 2017 Sep; 18(5):480-488. PubMed ID: 28365238
[TBL] [Abstract][Full Text] [Related]
34. Bevacizumab Combined with Platinum-Taxane Chemotherapy as First-Line Treatment for Advanced Ovarian Cancer: Results of the NOGGO Non-Interventional Study (OTILIA) in 824 Patients.
Sehouli J; Mustea A; Oskay-Özcelik G; Keller M; Richter R; Tomé O; Woopen H; Sommer-Joos AK; Grabowski JP; Armbrust R; Wimberger P
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638225
[TBL] [Abstract][Full Text] [Related]
35. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
Cohen MH; Gootenberg J; Keegan P; Pazdur R
Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
[TBL] [Abstract][Full Text] [Related]
36. Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study.
Ferrero JM; Hardy-Bessard AC; Capitain O; Lortholary A; Salles B; Follana P; Herve R; Deblock M; Dauba J; Atlassi M; Largillier R
Cancer; 2016 Oct; 122(20):3119-3126. PubMed ID: 27412268
[TBL] [Abstract][Full Text] [Related]
37. Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer. A Multicenter Phase II Trial by the Hellenic Oncology Research Group.
Saloustros E; Nikolaou M; Kalbakis K; Polyzos A; Christofillakis C; Kentepozidis N; Pistamaltzian N; Kourousis C; Vamvakas L; Georgoulias V; Mavroudis D
Clin Breast Cancer; 2018 Feb; 18(1):88-94. PubMed ID: 29153775
[TBL] [Abstract][Full Text] [Related]
38. BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer.
Hainsworth JD; Fang L; Huang JE; Karlin D; Russell K; Faoro L; Azzoli C
J Thorac Oncol; 2011 Jan; 6(1):109-14. PubMed ID: 21107290
[TBL] [Abstract][Full Text] [Related]
39. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.
van der Burg ME; Onstenk W; Boere IA; Look M; Ottevanger PB; de Gooyer D; Kerkhofs LG; Valster FA; Ruit JB; van Reisen AG; Goey SH; van der Torren AM; ten Bokkel Huinink D; Kok TC; Verweij J; van Doorn HC
Eur J Cancer; 2014 Oct; 50(15):2592-601. PubMed ID: 25096168
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of neoadjuvant chemotherapy with bevacizumab in advanced-stage peritoneal/ovarian cancer patients.
Kusunoki S; Terao Y; Hirayama T; Fujino K; Ujihira T; Ota T; Takeda S
Taiwan J Obstet Gynecol; 2018 Oct; 57(5):650-653. PubMed ID: 30342644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
